Blood plasma derivatives are fractionated components of blood plasma extracted through fractionation or isolation processes and are widely used in therapeutic, medical and manufacturing applications. Some key blood plasma derivatives include albumin, immunoglobulins, coagulation factors, protease inhibitors and other specialized proteins primarily used for treating bleeding disorders, immune deficiencies, infections and other medical conditions. The growing prevalence of chronic diseases and genetic disorders has significantly increased the demand for therapies based on blood plasma components. Albumin contributes to maintaining proper fluid balance in the body and transporting medications and nutrients in the bloodstream, making it vital in treating conditions involving blood loss or fluid accumulation. Immunoglobulins help strengthen the body’s immune response and are effective in managing various immunodeficiency disorders. There is also increasing research on harnessing the therapeutic benefits of novel plasma protein fractions.
The global Blood Plasma Derivatives Market is estimated to be valued at US$ 51.07 Bn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancements in plasma collection methods and fractionation technologies have enabled higher plasma yields and production of new plasma derivatives. Growing adoption of automated plasma collection platforms allows efficient volume plasma collection from donors. Emerging single-use consumables and closed-system configuration in fractionation plants ensure enhanced safety, workflow efficiency and plasma utilization. Ongoing research on identifying novel plasma protein fractions with therapeutic potential could expand the portfolio of plasma derivatives in the coming years. Monoclonal antibody therapies produced through recombinant technologies may gradually reduce demands for immunoglobulin treatments derived from human plasma, altering market dynamics. However, plasma-derived medicines continue demonstrating advantages over synthetic alternatives for certain indications, sustaining their clinical importance.
Porter’s Analysis
Threat of new entrants: The blood plasma derivatives market requires high capital investments and compliance with stringent regulations. This poses significant barriers for new companies.
Bargaining power of buyers: Individual consumers have low bargaining power in this market. However, large pharmaceutical companies and hospitals can leverage higher volumes to negotiate better prices.
Bargaining power of suppliers: A few major companies dominate the supply of raw materials like plasma. This gives them substantial bargaining power over manufacturers.
Threat of new substitutes: Currently, there are limited substitutes available for products derived from blood plasma. Technological advancements may introduce new alternatives in the future.
Competitive rivalry: The market is highly competitive with the presence of several global and regional players. Players compete based on product quality, reliability of supply, pricing, and manufacturing innovations.
Key Takeaways
The Global Blood Plasma Derivatives Market Size is expected to witness high growth over the forecast period of 2024 to 2031.
Regionally, North America is anticipated to dominate the market during the analysis timeframe. Factors such as strong reimbursement policies, rising prevalence of immune-related diseases and technological advancements are fueling market expansion in the region. Europe is also expected to exhibit robust growth in the near future due to growing plasma collections and increasing research funding.
Key players:
Key players operating in the blood plasma derivatives market are Iron Mountain, ARC, Access, Shred-it, Restore plc, Cintas, Proshred, National Document Shredding Service, Shred Station, Red Dog Shred, Shred-X, Secured Document Shredding, Shred Works, Guardian Data Destruction, EndoShred, Mobile Shred, ShredQuick, ProShred Chicago, Shreds Unlimited. Companies are investing heavily in R&D of advanced plasma therapeutics and building strategic partnerships with pharmaceutical vendors and collectors.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
